Other Income & Expense
Other Income (Expense)
Alnylam Pharmaceuticals Other Income (Expense) decreased by 379.0% to -$46.98M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 129.8%, from -$20.45M to -$46.98M. Over 4 years (FY 2021 to FY 2025), Other Income (Expense) shows a downward trend with a 5.6% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryOther
SignalContext dependent
VolatilityVolatile
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Significant fluctuations often relate to changes in interest rates, investment valuations, or currency volatility.
Detailed definition
The net total of income and expenses from non-operating activities, such as interest income, interest expense, and gains...
Peer comparison
Companies with large cash piles often show significant interest income here, while highly levered firms show interest expense.
Metric ID:
other_income_expense_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$42.17M | -$22.56M | -$65.74M | -$92.62M | -$82.99M | -$147.90M | -$18.41M | -$22.56M | -$44.38M | -$63.13M | -$21.28M | -$20.15M | -$59.78M | -$31.76M | -$88.80M | -$20.45M | -$19.16M | -$129.01M | -$9.81M | -$46.98M |
| QoQ Change | — | +46.5% | -191.4% | -40.9% | +10.4% | -78.2% | +87.6% | -22.5% | -96.8% | -42.2% | +66.3% | +5.3% | -196.7% | +46.9% | -179.6% | +77.0% | +6.3% | -573.4% | +92.4% | -379.0% |
| YoY Change | — | — | — | — | -96.8% | -555.6% | +72.0% | +75.6% | +46.5% | +57.3% | -15.6% | +10.7% | -34.7% | +49.7% | -317.2% | -1.5% | +68.0% | -306.2% | +89.0% | -129.8% |
Range-$147.90M – -$9.81M
CAGR+2.3%
Avg YoY Growth-61.8%
Median YoY Growth+4.6%
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's other income (expense)?
- Alnylam Pharmaceuticals (ALNY) reported other income (expense) of -$46.98M in Q1 2026.
- How has Alnylam Pharmaceuticals's other income (expense) changed year-over-year?
- Alnylam Pharmaceuticals's other income (expense) decreased by 129.8% year-over-year, from -$20.45M to -$46.98M.
- What is the long-term trend for Alnylam Pharmaceuticals's other income (expense)?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's other income (expense) has grown at a 5.6% compound annual growth rate (CAGR), from -$143.49M to -$178.43M.
- What does other income (expense) mean?
- Money made or lost from activities not related to the company's main business, like investments or interest.